Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10035375 | 0.94 | L3MBTL1 (0.34) | L3MBTL1TDP1TSHRALDH1A1MAPT | |
| SCHEMBL10035370 | 0.90 | MAOB (0.36) | L3MBTL1TDP1TSHRALDH1A1MAPT | |
| SCHEMBL10035367 | 0.87 | CDC25A (0.39) | L3MBTL1TDP1ALDH1A1MAPTKDM4E | |
| SCHEMBL10035369 | 0.86 | FAAH (0.37) | L3MBTL1TDP1ALDH1A1MAPTKDM4E | |
| SCHEMBL10035372 | 0.85 | FAAH (0.39) | ALDH1A1MAPTNPSR1HSD17B10 | |
| SCHEMBL10035365 | 0.85 | TDP1 (0.39) | L3MBTL1TDP1ALDH1A1MAPTKDM4E | |
| SCHEMBL10035368 | 0.81 | TDP1 (0.36) | L3MBTL1TDP1ALDH1A1KDM4ELMNA | |
| SCHEMBL10035371 | 0.81 | TDP1 (0.36) | L3MBTL1TDP1ALDH1A1KDM4ELMNA | |
| SCHEMBL9950614 | 0.80 | KDM4E (0.42) | L3MBTL1TDP1ALDH1A1MAPTKDM4E | |
| SCHEMBL30555481 | 0.80 | KDM4E (0.42) | L3MBTL1TDP1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674117-B2 | Organoboron compound and method for manufacturing the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8674117-B2 | Organoboron compound and method for manufacturing the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20120165550-A1 | Organoboron Compound and Method for Manufacturing the Same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-06-28 | — | — | US | disclosed |
| US-20120165550-A1 | Organoboron Compound and Method for Manufacturing the Same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165550-A1 | Organoboron Compound and Method for Manufacturing the Same | CYP2B6, CBR3, CBR1 | L3MBTL1 2201/4885TDP1 4009/4885TSHR 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.